Questions about an infusion device have scuttled Supernus Pharmaceuticals’ attempt to win approval of a Parkinson’s disease therapy. The complete response letter marks the second time in two years ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

The U.S. Infusion Therapy Device Market is on an upward trajectory. By 2029, the market is predicted to exceed $3.6 billion. Rising healthcare costs led to increased demand for infusion therapy ...

A Prescription Drug User Fee Act target date of February 1, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application (NDA) ...

For the fourth time already this month, the FDA has issued a notice formally bestowing a Class I label—denoting a heightened risk of serious injury or death—upon a recall of yet another drug delivery ...

(RTTNews) - Supernus Pharmaceuticals Inc. (SUPN) said that the U.S. Food and Drug Administration has acknowledged the resubmission of the new drug application or NDA for its SPN-830, an apomorphine ...

After a drawn-out approval process, medical equipment company Baxter International received regulatory clearance for a new infusion pump machine that is expected to help the company capture more of ...

Elevate your services and maximize profits with the BeneLift ® Pro – the next evolution in professional skincare technology. BOCA RATON, FLORIDA / ACCESS Newswire / October 17, 2025 / Beautinelle ...

Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine infusion ...

Purpose: The stability of meropenem in i.v. solutions stored in polyvinyl chloride (PVC) bags and an elastomeric infusion device at concentrations commonly used in home care was studied. Methods: ...